Aim: Doxorubicin (DOX), an anthracycline, is widely used in chemotherapy due to its effectiveness in fighting many cancers. Experimental and clinical studies prove that this drug damages non-targeted tissues (including cardiomyocytes) and reduces patients' quality of life during and after DOX treatment. The discovery of potent compounds as a protective tool to slow cardiomyocyte damage during the use of anti-cancer drugs such as DOX is crucial for both more effective cancer treatment and to improve patient's quality of life. Gossypin (GOS) is a flavonoid with several important properties, such as anti-cancer, analgesic, antioxidant, and anti-inflammatory. GOS shows supportive effects against oxidative stress and inflammation by activating antioxidant defense enzymes.
Material and Method: For the study, four groups were formed from H9c2 embryonic cardiomyocyte cells as Control, DOX (1 μM, 48 h), GOS25 (25 µg/ml, 48 h), and GOS50 (50 µg/ml, 48 h). In the study, Total antioxidant and oxidant status (TAS and TOS), levels of the inflammatory cytokines IL 1 beta and 6, and TNF α, lipid peroxidation levels as malondialdehyde (MDA), glutathione peroxidase (GSHPx), and glutathione (GSH) levels in the H9c2 embryonic cardiomyocyte cells were determined.
Results: The results showed that DOX treatment caused cell toxicity in the embryonic cardiomyocyte cells and increased TOS, IL 1 beta and 6, TNF α, and MDA levels while decreasing TAS, GSH, and GSHPx levels. This situation improved with GOS treatment.
Conclusion: As a result, it was determined that GOS treatment showed a protective effect in the DOX-induced cell toxicity model in H9c2 embryonic cardiomyocyte cell lines.
Oxidative Stress Inflammation H9c2 cardiomyocyte cell Gossypin Doxorubicin
sunuldu
| Birincil Dil | İngilizce |
|---|---|
| Konular | İnsan Biyofiziği |
| Bölüm | Araştırma Makalesi |
| Yazarlar | |
| Gönderilme Tarihi | 31 Ekim 2023 |
| Kabul Tarihi | 6 Aralık 2023 |
| Yayımlanma Tarihi | 31 Ocak 2024 |
| Yayımlandığı Sayı | Yıl 2024 Cilt: 6 Sayı: 1 |
Chief Editors
Prof. Dr. Berkant Özpolat, MD
Department of Thoracic Surgery, Ufuk University, Dr. Rıdvan Ege Hospital, Ankara, Türkiye
Editors
Prof. Dr. Sercan Okutucu, MD
Department of Cardiology, Ankara Lokman Hekim University, Ankara, Türkiye
Assoc. Prof. Dr. Süleyman Cebeci, MD
Department of Ear, Nose and Throat Diseases, Gazi University Faculty of Medicine, Ankara, Türkiye
Field Editors
Assoc. Prof. Dr. Doğan Öztürk, MD
Department of General Surgery, Manisa Özel Sarıkız Hospital, Manisa, Türkiye
Assoc. Prof. Dr. Birsen Doğanay, MD
Department of Cardiology, Ankara Bilkent City Hospital, Ankara, Türkiye
Assoc. Prof. Dr. Sonay Aydın, MD
Department of Radiology, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Türkiye
Language Editors
PhD, Dr. Evin Mise
Department of Work Psychology, Ankara University, Ayaş Vocational School, Ankara, Türkiye
Dt. Çise Nazım
Department of Periodontology, Dr. Burhan Nalbantoğlu State Hospital, Lefkoşa, North Cyprus
Statistics Editor
Dr. Nurbanu Bursa, PhD
Department of Statistics, Hacettepe University, Faculty of Science, Ankara, Türkiye
Scientific Publication Coordinator
Kübra Toğlu
argistyayincilik@gmail.com
Franchise Owner
Argist Yayıncılık
argistyayincilik@gmail.com
Publisher: Argist Yayıncılık
E-mail: argistyayincilik@gmail.com
Phone: 0312 979 0235
GSM: 0533 320 3209
Address: Kızılırmak Mahallesi Dumlupınar Bulvarı No:3 C-1 160 Çankaya/Ankara, Türkiye
Web: www.argistyayin.com.tr